Henry Schein, Inc. (NASDAQ:HSIC) released its quarterly earnings data on Tuesday, August 8th. The company reported $1.75 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.73 by $0.02, RTT News reports. The business had revenue of $3.06 billion during the quarter, compared to analysts’ expectations of $3.05 billion. Henry Schein had a net margin of 4.59% and a return on equity of 19.91%. The company’s revenue for the quarter was up 6.4% on a year-over-year basis. During the same period in the previous year, the company earned $1.64 EPS. Henry Schein updated its FY17 guidance to $7.17-7.30 EPS.
Henry Schein (NASDAQ HSIC) traded down 0.07% on Friday, reaching $169.49. 525,408 shares of the company’s stock were exchanged. Henry Schein has a 1-year low of $146.23 and a 1-year high of $186.99. The stock’s 50 day moving average price is $179.49 and its 200 day moving average price is $175.49. The firm has a market capitalization of $13.40 billion, a price-to-earnings ratio of 24.77 and a beta of 1.09. Henry Schein’s stock is going to split on the morning of Friday, September 15th. The 2-1 split was announced on Wednesday, August 16th. The newly created shares will be issued to shareholders after the closing bell on Thursday, September 14th.
Several equities research analysts have recently issued reports on the stock. Piper Jaffray Companies assumed coverage on shares of Henry Schein in a research report on Monday, June 12th. They set a “neutral” rating and a $200.00 price objective for the company. Jefferies Group LLC reaffirmed a “hold” rating and set a $177.00 price objective on shares of Henry Schein in a research report on Friday, July 21st. Zacks Investment Research cut shares of Henry Schein from a “buy” rating to a “hold” rating in a research report on Friday, June 23rd. Credit Suisse Group reaffirmed a “hold” rating and set a $160.00 price objective on shares of Henry Schein in a research report on Thursday, July 13th. Finally, Stifel Nicolaus reaffirmed a “hold” rating on shares of Henry Schein in a research report on Thursday, July 6th. One analyst has rated the stock with a sell rating, ten have issued a hold rating and seven have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $185.56.
TRADEMARK VIOLATION NOTICE: This news story was originally published by BNB Daily and is the sole property of of BNB Daily. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.baseball-news-blog.com/2017/08/19/henry-schein-inc-nasdaqhsic-posts-quarterly-earnings-results-beats-estimates-by-0-01-eps-updated.html.
Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of Henry Schein by 3.0% in the second quarter. Vanguard Group Inc. now owns 8,086,317 shares of the company’s stock worth $1,479,959,000 after buying an additional 236,862 shares during the period. FMR LLC boosted its stake in shares of Henry Schein by 0.4% in the second quarter. FMR LLC now owns 6,921,367 shares of the company’s stock worth $1,266,749,000 after buying an additional 24,935 shares during the period. BlackRock Inc. boosted its stake in shares of Henry Schein by 1.8% in the second quarter. BlackRock Inc. now owns 5,696,685 shares of the company’s stock worth $1,042,607,000 after buying an additional 101,406 shares during the period. State Street Corp boosted its stake in shares of Henry Schein by 1.3% in the first quarter. State Street Corp now owns 3,675,674 shares of the company’s stock worth $624,760,000 after buying an additional 48,469 shares during the period. Finally, Mackenzie Financial Corp boosted its stake in shares of Henry Schein by 4.7% in the first quarter. Mackenzie Financial Corp now owns 1,728,230 shares of the company’s stock worth $293,747,000 after buying an additional 76,794 shares during the period. 90.60% of the stock is owned by hedge funds and other institutional investors.
Henry Schein Company Profile
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with MarketBeat.com's FREE daily email newsletter.